Fda Authorizes Monoclonal Antibody Covid Treatment For All High Risk Children
The combination treatment was authorized for use in children aged 12 and over and in adults in February 2021. In a statement, Patrizia Cavazzoni, MD, director of the FDA’s Center for Drug Evaluation and Research, said that the extension of the authorization means that “all patients at high risk of severe COVID-19, including children and newborn babies, have an option for treatment and post-exposure prevention.” Cavazzoni added that children under one year of age who are exposed to the virus “may be at particularly high risk for severe COVID-19” and that the authorization “addresses the medical needs of this vulnerable population....